Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria
- Ockenhouse, CF; Sun, PF; Lanar, DE; Wellde, BT; Hall, BT; Kester, K; Stoute, JA; Magill, A; Krzych, U; Farley, L; Wirtz, RA; Sadoff, JC; Kaslow, DC; Kumar, S; Church, LWP; Crutcher, JM; Wizel, B; Hoffman, S; Lalvani, A; Hill, AVS; Tine, JA; Guito, KP; de Taisne, C; Anders, R; Horii, T; Paoletti, E; Ballou, WR;
Publication Year 1998-06, Volume 177, Issue #6, Page 1664-1673
- Journal Title
- JOURNAL OF INFECTIOUS DISEASES
- Publication Type
- Journal Article
- Candidate malaria vaccines have failed to elicit consistently protective immune responses against challenge with Plasmodium falciparum. NYVAC-Pf7, a highly attenuated vaccinia virus with 7 P. falciparum genes inserted into its genome, was tested in a phase I/IIa safety, immunogenicity, and efficacy vaccine trial in human volunteers. Malaria genes inserted into the NYVAC genome encoded proteins from all stages of the parasite's life cycle. Volunteers received three immunizations of two different dosages of NYVAC-Pf7. The vaccine was safe and well tolerated but variably immunogenic. While antibody responses were generally poor, cellular immune responses were detected in >90% of the volunteers. Of the 35 volunteers challenged with the bite of 5 P. falciparum-infected Anopheles mosquitoes, 1 was completely protected, and there was a significant delay in time to parasite patency in the groups of volunteers who received either the low or high dose of vaccine compared with control volunteers.
- UNIV CHICAGO PRESS
- GENETICALLY ENGINEERED POXVIRUSES; GLYCOPROTEIN-D; BIOLOGICAL-ACTIVITY; ESCHERICHIA-COLI; ENVELOPE GENE; LIVE VACCINES; VIRUS; PROTECTION; PROTEIN; HERPES
- Publisher's Version
- Rights Notice
- Refer to copyright notice on published article.
Creation Date: 1998-06-01 12:00:00Last Modified: 0001-01-01 12:00:00